Contract notice: Pharmaceutical products Tender, Germany - 14864540

Procurement Summary

Country : Germany

Summary : Contract notice: Pharmaceutical products

Deadline : 31 Aug 2019

Other Information

Notice Type : Tender

TOT Ref.No.: 14864540

Document Ref. No. : 273209-2017

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : KKH KAUFMÄNNISCHE KRANKENKASSE
Office Name: KKH Kaufmännische Krankenkasse
Address: Karl-Wiechert-Allee 61
Town: Hanover
Postal Code: 30625
Contact Point: zentrales Arzneimittelmanagement
Attention: Sven Seißelberg
Phone: +49 5112802-3376
Fax: +49 5112802-3396
Germany
Email :sven.seisselberg@kkh.de
URL :www.kkh.de

Tender Details

Object of the contract
Pharmaceutical products

Description: Contract notice: Pharmaceutical products

Authority Type: Body governed by public law
Contact Nature: Supplies
Procedure: Open procedure
Document: Contract notice
Regulation: European Union
Award criteria: Not specified
CPV code: 33600000, 33600000
CPV Description: Conclusion of non-exclusive discount agreements pursuant to - 130a para. 8 SGB V to teriparatide (ATC: H05AA02) with the possibility to close at any time under the so-called open-house procedure, With all appropriate pharmaceutical companies, discount agreements pursuant to - 130a Paragraph 8 SGB V above the above--In accordance with section 130a para. 8 SGB V, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies shall be entitled to conclude or join a contract of sale under an open-house procedure The above active substancePharmaceutical companies that are involved in this process can benefit from the And the contract. At the same time as the requirement of the contract documents, the pharmaceutical company shall be required to submit appropriate authorizations for medicinal products with the above-mentioned. Active substance. The detection may e.g. About a corresponding excerpt from AMISDatabase. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits and submits the requested participation documents in full and signed. A contract is concluded with every pharmaceutical company that fulfills the prerequisites for participation. An exclusivity is not given. The accession or the TreatyCan be concluded at any time and under the same conditions. Individual contract negotiations are not carried out.

The earliest start of the contract is 1.9.2017. Should the KKH during the term of the contract for the active substances carry out an invitation to tender for exclusive contracts in the form of the open procedure, the contracts concluded within the scope of this publication shall beIn accordance with the contractual provisions.

This publication is not a public procurement contract within the meaning of the Public Procurement Direc- tive of Directives. In order to ensure the widest degree of transparency for the intended conclusion of the contract, the supplement is published in the Official Journal of the European CommunitiesThe Union. In the absence of a corresponding publication form, the contract notice shall be used. The resulting conceptual specifications, such as the procedure name "open procedure", are solely due to the use of this publication form and to the publishing platform(S), which are not required for legal reasons, is not linked to this.

A contract shall be concluded no later than 10 days after publication of this notice.

Information and formalities necessary for evaluating if requirements are met:

- Or commercial register extract in copy (at the time of the expiry of the bid period6 months), - Signed and stamped declaration of authenticity according to participation documents.


Internet address (URL): www.kkh.de
Directive: Classical Directive (2004/18/EC)

Documents

 Tender Notice